I have extensively used these lentiviral vectors to perform KD experiments, and they work. We have performed experiments in different cell types, from macrophages to epithelial cells, from both mice and humans. I totally recommend it.
SHCLNV
MISSION® shRNA
Lentiviral Particles
MISSION® shRNA
1 of 2 reviewers received a sample product or took part in a promotion
Sign Into View Organizational & Contract Pricing
About This Item
UNSPSC Code:
41106609
To order shRNA please search for your gene of interest.
Skip To
Looking for similar products? Visit Product Comparison Guide
Related Categories
1 of 4
This Item | CSTVRS | SHCLNG | SHCLND |
|---|---|---|---|
| technique(s) capture ELISA: 106 VP/mL using p24 | technique(s) capture ELISA: 106 VP/mL using p24 | technique(s) - | technique(s) - |
| shipped in dry ice | shipped in dry ice | shipped in dry ice | shipped in dry ice |
| storage temp. −70°C | storage temp. −70°C | storage temp. −70°C | storage temp. −20°C |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 200 |
General description
Our comprehensive shRNA product offering consists of over 150,000 pre-cloned shRNA constructs targeting more than 15,000 human and 15,000 mouse genes. The library is available in: gene family sets: gene collections related to specific functional classes such as kinases and ion channels; gene taget sets, sets of shRNA clones that target your favorite gene; and individual shRNA clones. Our shRNA and lentiviral manufacturing platforms utilize dedicated laboratories featuring state-of-the-art robotics, liquid handling and laboratory information management systems (LIMS) to provide superior quality and service for your RNAi research needs.
Lentiviral particles are ideal for transducing a wide range of cell lines. VSV-G Psuedotyping of the MISSION® lentiviral particles allows for entry into a wide range of cells. In addition, lentiviral particles stably integrate the shRNA into the genomes of both dividing and non-dividing cell lines. The MISSION bioproduction team regularly produces high quality lentivirus, so that our customers can get straight to their RNAi experiment without wasting precious time on tedious lentiviral production. Our minimum titer is 106 VP/mL. Unlike adenoviral infections that require vast excesses, lentiviral transduction is efficient enought allow for MOI as low as 1.
Application
Other Notes
To see protocols and application data please visit sigma.com/shrna.
Legal Information
Use of this product is subject to one or more license agreements.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
alpha-Actinin-4 confers radioresistance coupled invasiveness in breast cancer cells through AKT pathway
Desai S, et al.
Biochimica et Biophysica Acta - Molecular Cell Research, 1865(1), 196-208 (2018)
Bile acids reduce endocytosis of high-density lipoprotein (HDL) in HepG2 cells.
Rohrl C, Eigner K, Fruhwurth S, et al.
PLoS ONE, 9(7), e102026-e102026 (2014)
Xia Liu et al.
Oncology letters, 16(5), 5868-5874 (2018-10-20)
Ovarian cancer (OC) has the highest fatality rates of all gynecological malignancies worldwide. The epithelial-to-mesenchymal transition (EMT) serves an essential role in the progression of OC. An improved understanding of the molecular mechanism underlying EMT in OC may increase the
α-Actinin-4 confers radioresistance coupled invasiveness in breast cancer cells through AKT pathway.
Sejal Desai et al.
Biochimica et biophysica acta, 1865(1), 196-208 (2017-10-23)
Acquired radioresistance accompanied with increased metastatic potential is a major hurdle in effective radiotherapy of breast cancers. However, the nature of their inter-dependence and the underlying mechanism remains largely intangible. By employing radioresistant (RR) cell lines, we herein demonstrate that
Vera Mugoni et al.
Cell research, 29(6), 446-459 (2019-04-27)
Although targeted therapies have proven effective and even curative in human leukaemia, resistance often ensues. IDH enzymes are mutated in ~20% of human AML, with targeted therapies under clinical evaluation. We here characterize leukaemia evolution from mutant IDH2 (mIDH2)-dependence to
Related Content
Instructions
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service